A Drug-related Problem Risk Assessment Tool (DRP-RAT) for use by home care practical nurses

Similar documents
Selecting the right patient for medication reviews

Patient Information Leaflet Lodine* SR Tablets 600mg (etodolac) 1. WHAT LODINE SR TABLETS ARE AND WHAT THEY ARE USED FOR

PRODUCT MONOGRAPH. FLOCTAFENINE Floctafenine Tablets 200 mg and 400 mg THERAPEUTIC CLASSIFICATION. Anti-inflammatory, Analgesic

This leaflet answers some common questions about Momex SR Tablets.

PHOLCODINE. Please follow the instructions on the packaging of the medicine you purchased and in this leaflet before you start using pholcodine.

PRESCRIBING IN THE ELDERLY. CARE HOME PHARMACY TEAM Bhavini Shah, Eleesha Pentiah & Puja Vyas

All medicines have risks and benefits. Your doctor has weighed the risks of you taking Triprim against the benefits he or she expects it will have.

Patient information sheet: BuTrans Patch This information should be read in conjunction with the Taking Opioids for pain information leaflet

Adepu and Adusumilli: Drug-related Problems in Patients with Chronic Diseases in South India

Detecting inappropriate prescribing for older patients at the community pharmacy

NHS Greater Glasgow And Clyde Pain Management Service. Information for Adult Patients who are Prescribed. Pregabalin. For the Treatment of Pain

Medication Management When Caring for Seniors at Home

For many people, the warnings for a medication can read like the fine print of a home mortgage.

Ketorolac injection. Supportive care

PATIENT INFORMATION LEAFLET FOR TEXA 10 mg TABLETS AND TEXA SYRUP PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM:

If you wake up to urinate 2 or more times a night, ask your doctor about NOCTIVA

Diuretics Looking for more health information?

Pain CONCERN. Medicines for long-term pain. Opioids

TRIPROLIDINE. Please read this leaflet and the packaging of the medicine you purchased, carefully before you start using triprolidine.

IMPORTANT: PLEASE READ

Geriatric Medicine Clerkship Orientation. Aval-Na Ree Green (modified by Huai Cheng)

Perjeta Contains the active ingredient pertuzumab (rch)

Amal AL-Anazi, BSc.(Pharm) Medication Safety Officer In Eastern Region

Methotrexate for inflammatory bowel disease: what you need to know

NEOFEN 60 mg suppository

Welcome participants, introduce the expert, and briefly outline today s session.

TREANA 5mg and 10mg Film-coated Tablets

Consumer Medicine Information

21st century community pharmacy

1. What Solpadol is and what it is used for

Midazolam Injection Midazolam

Managing medicines in older people. Jane Noble and Caroline Ralph

Duro-Tuss Dry Cough Liquid plus Nasal Decongestant Pholcodine (fol-co-dean); Pseudoephedrine hydrochloride (sue-doe-eff-eh-drine hydro-klor-ide)

Case Study Activity: Strategies to Support the Safe Use of Acetaminophen

PATIENT INFORMATION LEAFLET ZOXADON TABLETS RANGE

Pharmaceutical Care for Geriatrics

Onglyza CONSUMER MEDICINE INFORMATION

Comprehensive Medication History Interview Form

PACKAGE LEAFLET: INFORMATION FOR THE USER. DF118 Tablets 30mg (Dihydrocodeine Hydrogen Tartrate)

PACKAGE LEAFLET: INFORMATION FOR THE USER. EASOFEN MAX STRENGTH 400mg FILM-COATED TABLETS. Ibuprofen

RANIBOS 150mg Film-coated tablets; 300mg Film-coated tablets

Flecainide BNM. Please read this leaflet carefully before you start taking Flecainide BNM.

Have you already tried different drugs for your schizophrenia? Here s another option you and your doctor may want to consider.

PACKAGE LEAFLET: INFORMATION FOR THE USER. Dantrium 25 mg Capsules / Dantrium 100 mg Capsules Dantrolene sodium

Deconstructing Polypharmacy. Alan B. Douglass, M.D. Director

SPASMEX FORTE 5mg tablets

Aripiprazole Accord 5, 10, 15 and 30 mg film-coated tablets

PLEASE FILL OUT & RETURN

NHS Greater Glasgow And Clyde Pain Management Service. Information for Adult Patients who are Prescribed. Duloxetine. For the Treatment of Pain

Essential Shared Care Agreement: Lithium

XYZAL 5 MG FILM-COATED TABLET

It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.

Package Leaflet: Information for the User. Kemadrin tablets 5 mg procyclidine hydrochloride

Package leaflet: Information for the user. Cyclizine Lactate 50 mg/ml Injection

Safe Medication Use. Patient Teaching Slides

Package leaflet: Information for the patient. Torarese 2.5 mg tablets Torarese 5 mg tablets Torarese 10 mg tablets Torarese 20 mg tablets.

METHYLDOPA 250 mg Film-coated Tablets

PHARMACY ACTION COLD & FLU DAY & NIGHT paracetamol, pseudoephedrine hydrochloride, chlorphenamine maleate

paracetamol Please read this leaflet carefully before you are given Paracetamol BNM.

Package leaflet: Information for the user. Co-Codamol 30mg/500mg Capsules (Codeine Phosphate Hemihydrate and Paracetamol)

Cosudex. Bicalutamide 50 mg Tablets CONSUMER MEDICINE INFORMATION

Myfortic Transplant Coordinator Survey: Defining the perceptions of generic mycophenolate mofetil

Consumer Medicine Information

From medicines reconciliation to medicines review. Dr. Fatma Karapinar Hospital pharmacistepidemiologist

AVIOMARIN 50 mg tablets

EDEMID FORTE 500mg tablets

PATIENT INFORMATION LEAFLET TEXAMER

of LDL and HDL cholesterol.

POLLENTYME S and Tabs Pharma Dynamics (Pty) Ltd Version: July 2017 (G1639) Word copy of G1639 PATIENT INFORMATION LEAFLET FOR POLLENTYME S AND TABS

YOUR GUIDE TO ARIPIPRAZOLE Patient/Caregiver Information Brochure

Medical History Form

PGEU GPUE. Pharmaceutical Group of European Union Groupement Pharmaceutique de l Union Européenne

It is used to treat or prevent upset stomach and throwing up. What do I need to tell my doctor BEFORE I take this drug?

For the Patient: Vemurafenib Other names: ZELBORAF

Patient/Caregiver Information Brochure For Bipolar I Disorder in Adolescents

MY DISCUSSION GUIDE. Get the most out of your OCALIVA treatment.

Ceclor CD cefaclor monohydrate sustained release tablets

Annual Exam Review. Medications: Medication Strength (mg) Directions ( how many pills and how many times a day)

Dulcolax 5 mg, film-coated tablets

Medication Safety Challenges in Older Adults

RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets

Bisacodyl Laxative (Pharmacy Health)

This leaflet answers some common questions about ATIVAN. It does not contain all of the available information.

PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: Read this entire leaflet carefully before you start taking DYNAFLOC.

Colofac mebeverine hydrochloride

Package leaflet: Information for the user. Colecalciferol 3000 IU/ml Oral Solution (colecalciferol)

PATIENT INFORMATION LEAFLET

How it works. Use in children

MIDAZOLAM APOTEX Solution for Injection Contains the active ingredient midazolam

Buprenorphine Patch (Transtec Patch)

Pharmacology in the Elderly

ZOLPIDEM PHARMACOR Zolpidem tartrate

Coldrex MaxGrip Lemon Powder for oral solution

ENSURING EXCELLENCE IN PRESCRIBING FOR OLDER ADULTS

Wellness along the Cancer Journey: Palliative Care Revised October 2015

Olanzapine generichealth tablets Olanzapine benzoate

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. SYLVANT pronounced SILL-vant siltuximab for injection

Transcription:

A Drug-related Problem Risk Assessment Tool (DRP-RAT) for use by home care practical nurses Maarit Dimitrow, PhD (Pharm) University of Helsinki Finland www.helsinki.fi/yliopisto

Background The demand for long-term home health care services for the aged is growing Those needing home care (HC) are increasingly older and have more complex health problems In Finland, practical nurses (PNs) have 3-year vocational education that concentrates mainly on technical nursing rather than pharmacotherapy www.helsinki.fi/yliopisto

Background PNs working in HC are those who make regular home visits to the elderly => PNs are in a key position to monitor and notice changes in their clients health status including positive and negative outcomes of possible drug treatments Due to lacking physician resources in HC, the physician-conducted home visits are rare => PNsʼ role in medication risk management is pronounced www.helsinki.fi/yliopisto

DRP-RAT PNs need a practical tool for identifying problems related to drug treatments => Development and validation an easy-to-use Drugrelated Problem Risk Assessment Tool (DRP-RAT) for PNs caring for home-dwelling aged 65 years PNs need training to use the Tool PNs conduct the risk assessments during their normal home visits in collaboration with the HC client (if possible) PNs report their risk assessments to other healthcare providers www.helsinki.fi/yliopisto

Development of the draft DRP-RAT 1. Two systematic literature reviews 2. Expertice of the research group 3. Consultation of a geriatrician not involved in the research group Content validation of the draft DRP- RAT 3-round Delphi survey with a panel of 18 experts in geriatric care and pharmacotherapy Feasibility of the final DRP-RAT Conducted among practical nurses in home care of two towns in southern Finland Testing the validity of the final DRP- RAT in clinical practice An experienced geriatricianʼs reliability evaluation of PNsʼ risk assessments Geriatrician identifyed the clinically most significant DRPs Phase I Development Phase II Validation process 23.11.2017 5

Faculty of Pharmacy / Maarit Dimitrow 23.11.2017 6

Is there anyone who determines whether the client takes his/her medicines? (added based on the feasibility study)

OTC High risk medicines Polypharmacy

Involving the client and his/her proxy to clientʼs care Fall tendency Symptoms suggestive of ADRs

Clientʼs health status Potential problems with transfer of clinical patient data

Involving the client/care giver in clientʼs care Adherence

Interventions for resolving the problems Increases the awareness among PNs and the aged of options to improve medication safety

Symptoms suggestive of ADRs When developing the DRP-RAT we had to take into account the PNʼs ability to answer the items of the tool It is not useful to ask the PNs if the clients uses anticholinergic medicines, sedatives or medicines that may cause hyponatremia etc. Thus, we decided to ask the PNs if their clients have symptoms suggestive of adverse drug reactions (ADRs) that these problematic medicines may cause The symptoms listed in the Tool include ADRs of a wide range of medicines (e.g., anticholinergics, sedatives, neuroleptics, diuretics, hypoglycemic, diuretics, blood pressure medications, etc.) www.helsinki.fi/yliopisto

23.11.2017 14

Main results of the feasibility study Participants: 36 PNs Time spent to complete the DRP-RAT 10-45 minutes; mean 20±8 minutes The PNs identified 88% of the risk medicines listed in the Tool Challeges the PNs met in completing the tool Generic names of medicines Time resctrictions Short client contacts Faculty of Pharmacy / Maarit Dimitrow www.helsinki.fi/yliopisto 23.11.2017 15

Geriatricianʼs reliability evaluation of PNsʼ risk assessments Faculty of Pharmacy / Maarit Dimitrow www.helsinki.fi/yliopisto 23.11.2017 16

Outline of the study Participants: A clinically experienced geriatrician 26 home care PNs 46 home care clients 1. First phase of the study: The PNs conducted risk assessment for their clients using the DRP-RAT during their normal home visits The PNsʼ risk assessments were forwarded to the research geriatrician ifaculty of Pharmacy / Maarit Dimitrow www.helsinki.fi/yliopisto 23.11.2017 17

2. Second phase of the study: DRP risk assessments and medication reviews by the geriatrician The geriatrician reviewed the same clientsʼ medications using three different review methods: Method 1: Review based on the PN-completed DRP-RAT information and the medication list printed from the health centerʼs medical records Method 2: Review based on the health center s medical records ( gold standard ) of the study) Medical records encompass the following patient data: a) visits in health center, b) clinical examinations (health status, anamnesis, conclusions), c) medication lists, d) laboratory test results, e) hospitalizations, f) HC workers open comments about their home visits Method 3: Review based on Methods 1 and 2 together = all client information available Faculty of Pharmacy / Maarit Dimitrow 23.11.2017 18

Geriatricianʼs assessment of clinical importance of the items in identifying risks for clinically significant drug-related problems in study sample Based on each review the geriatrician was asked to classify the patients as an risk patient or not an at risk patient Risk patient: a patient is at risk for clinically significant DRPs needing more comprehensive medication review If the geriatrician classified the client as an at-risk patient based on Method 1 (PN-completed DRP- RAT information and medication list) she was asked to tick those PN-identified risk predicting notes in the Tool that she regarded as clinically significant risk factors Faculty of Pharmacy / Maarit Dimitrow www.helsinki.fi/yliopisto 23.11.2017 19

Traffic lights of risks Risk predicting factor Has the client had any of the following symptoms in the last 4 weeks? drowsiness, fatigue, skin rash or itch, dizziness, urination problems, muscle pains, nausea, diarrhea, constipation, dizziness when getting up, recurrent falls, swellings, memory problems, confusion, visual problems, stiffness, troubles in walking, low blood pressure; systolic pressure under 110 mmhg (n=44) Does the client have more than one physician involved in his/her care? (e.g., general practitioners, specialists, private practitioners) (n=44) Has the client had more than one fall in the past 12 months? (n=44) Does the client use any of the following medicines (please check the ones used)? amiodarone, carbamazepine, digoxin, fluoxetine, lithium, methotrexate, theophylline, warfarin (n=44) Prevalence in the study sample 40 (yes) (91%) 22 (yes) (50%) 18 (yes) (41%) 16 (yes) (36%) Clinical Importance of the of the questions in identifying risks for clinically significant drug-related problems 26 20 18 14 Faculty of Pharmacy / Maarit Dimitrow 23.11.2017 20

Risk predicting factor Traffic lights of risks Has the client had troubles in a) remembering to take the medicines? b) following the medicines regimen? c) knowing what his or her medicines are used for? d) affording the medicines (i.e., economic problems)? e) opening the drug bottles or packages or managing with medicines related therapeutic devices? (n=44) Does the client use medicines that a) relieve pain by reducing inflammation (does not apply to paracetamol)? b) elevate the rate of urination (diuretics)? c) are intended to lower the cholesterol level (statins)? ) d) the physician does not know about? (n=44) Have the client's relatives/proxies expressed their concern about the client's medicine use? (n=43) Has the client started a new medicine in the last 4 weeks? (excluding different brands of the same active incredient) (n=44) Prevalence in the study sample 30 (yes) (68%) 35 (yes) (80%) 7 (yes) (16%) 7 (yes) (16%) Clinical Importance of the of the questions in identifying risks for clinically significant drug-related problems 11 8 7 6 Farmasian tiedekunta / Henkilön nimi / Esityksen nimi 23.11.2017 21

Implications for practice DRP-RAT: Can assist in identifying clients needing medication review Provides additional information for pharmacists who conduct medication reviews Educational implications www.helsinki.fi/yliopisto

An example of an operational model (case Lohja, Toivo et. al. 2017) Practical Nurses Update of the medication lists Risk assessment with DRP-RAT (Clinical tests) Coordinating pharmacist Preliminary assessent of the medication using Medication lists Risk assessments Available databases (pharmacokinec and -dynamic interactions) Coordinating pharmacist and physician Shared decisionmaking for further actions Physician, nurse, pharmacist Case-spesific actions, e.g., prescription review, MR, CMR (physician) Carrying out the decided actions (pharmacist) Follow up after 3 months (nurse)

First assignment Think ideas how to implement the DRP-RAT in your health care system? Other ideas to benefit the DRP- RAT? Faculty of Pharmacy / Maarit Dimitrow www.helsinki.fi/yliopisto 23.11.2017 24

Second assignment The case of Mrs. K Mrs. K is an 86 years old lady, living alone in her own house. Home care practical nurse Miss. A visits her 3 times a week. Mrs. K suffers from cardiac failure, hypertension, diabetes mellitus, osteoarthritis, depression, troubles with sleeping and constipation. Earlier, she also has had several urinary tract infections. Most of her medicines are dispensed by automated dose dispensing (i.e., regularly used medicines are machine packed into unit dose bags for each time of administration), home care practical nurse administers the rest (i.e., buprenorphine plaster, local estrogen). Mrs. K takes her daily tablets (except the plasters and local estrogen) on her own. During the last weeks Miss. A has noticed that Mrs. K has been tired and forgetful, from time to time she has not taken all her dispensed medicines. Miss. A wondered if the used medicines could cause these symptoms. As Miss. A had been trained on the content and use of the DRP-RAT by her home care organization, she conducted the medication risk assessment during her next home visit to Mrs. K. She also printed Mrs. K medication list from health centre s medical records and compared the medicines Mrs. K. really uses with the medication list. Farmasian tiedekunta / Henkilön nimi / Esityksen nimi www.helsinki.fi/yliopisto 23.11.2017 25

The case of Mrs. K Which do you think are the most essential PN-reported risk predicting factors in the completed DRP-RAT? Justify your opinion Which medicines and/or what combination of medicines that Mrs. K uses may cause her symptoms? Use databases, Beers criteria etc. Do you agree with the PNʼs recommendations for action? If not, what would you prefer Mrs. K for further actions? Justify your opinion Farmasian tiedekunta / Henkilön nimi / Esityksen nimi www.helsinki.fi/yliopisto 23.11.2017 26

Thank You! Farmasian tiedekunta / Henkilön nimi / Esityksen nimi www.helsinki.fi/yliopisto 23.11.2017 27